Vertex' orphan Kalydeco squeezes into Germany
This article was originally published in Scrip
Executive Summary
Vertex's orphan drug for cystic fibrosis Kalydeco (ivacaftor) has, by the skin of its teeth, been spared a more rigorous AMNOG benefit assessment in Germany after the committee in charge of the process, the G-BA, disregarded a previous opinion that the drug generated too much money.